PUBLISHER: Acute Market Reports | PRODUCT CODE: 1192950
PUBLISHER: Acute Market Reports | PRODUCT CODE: 1192950
Wilson's Disease Drugs Market - Growth, Future Prospects and Competitive Analysis, 2022 - 2030
Wilson's disease occurs equally in both male and female population, but research studies have cited differences in the sex specific phenotypes. Hepatic symptoms occurs 55%-60% more in the female population. Frank psychosis is more prevalent in the male population which is often mistaken as a bipolar disorder or schizophrenia. In the near future gene therapy can be used to transfer ATPB7 gene if sufficient transgene of ATPB7 is expressed in the liver cells for longer duration of time. It is very important for the accurate diagnosis of Wilson's disease or could lead to fatal consequences if not done appropriately.
The early diagnosis of Wilson's disease is primarily based on the multiple indications such as hepatic, neuropsychiatric, ophthalmic and others. The chelators are the first line of therapy which includes Penicillamine and trientine. Zinc acetate is considered as the only mineral prescribed for the patients that are resistant to chelators therapy. Data mining and market estimation is covered in the scope of the report to understand the opportunity for novel drug discovery in the treatment of Wilson's disease.
Market estimation and data mining is helpful in understanding the current treatment regimen and regulatory norms prevalent in different geographical regions.
Attractive investment proposition gives genuine understanding of the disease prevalence in different countries through data mining and the approach adopted to consider the treatment regimen for Wilson's disease. Product portfolio gives an idea about the different dietary supplements enriched in zinc primarily used for the management of Wilson's disease. Recent news coverage helps us to understand the strategic partnership taking place in the healthcare segment to lunch novel drug discovery for the treatment of Wilson's disease. The manufacturers that are active in the treatment of Wilson's disease are Kadmon Holdings, Inc., Merck & Co., Noble Pharma Co., Ltd., Teva Pharmaceutical Industries Limited, Tsumura & Co., Valeant Pharmaceuticals International, Inc., VHB Life Sciences, Inc. and Wilson Therapeutics AB.
Wilson's disease is a rare hereditary disorder which occurs due to the accumulation of copper in different body organs such as liver, brain, eyes and other vital organs. The disease takes place due to the mutation in ATP7B gene. The prevalence rate of Wilson's disease is 1 in 30,000 persons, usually diagnosed in young and adult age group. Hepatic indications are first diagnosed in the disease manifestation of Wilson's disease on account of reduced biliary excretion of copper results in excessive accumulation of copper in liver. The early symptoms manifested in liver indications are tiredness, hepatitis with elevated levels of gamma-glutamyl transpeptidase, alanine aminotransferase and aspartate aminotransferase. The neuropsychiatric symptoms are manifested in the later stages of the disease manifestation with the basal ganglia hampering the coordinate movement. The major symptoms are Parkinsonism, tremors, ataxia, dystonia and seizures. In approximately 90 % of the patients exhibiting neuropsychiatric symptoms shows the development of Kayser-Fleishcer rings (deposition of copper) in the cornea region of the eyes. The manufacturers that are active in the treatment of Wilson's disease are Kadmon Holdings, Inc., Merck & Co., Noble Pharma Co., Ltd., Teva Pharmaceutical Industries Limited, Tsumura & Co., Valeant Pharmaceuticals International, Inc., VHB Life Sciences, Inc. and Wilson Therapeutics AB.
The primary diagnosis of Wilson's disease is complicated as the symptoms are similar to other diseases such as hepatitis C, seizures, jaundice, heavy metal poisoning and cerebral palsy. Even though Wilson's disease is a genetic hereditary disease but a person is not likely to acquire the ATPB7 mutation on receiving only one abnormal gene from either of the parents. The disease management is entirely focused on compensating for the abnormal copper metabolism. As if now the chelators are the first line of treatment for achieving symptomatic relief in patients suffering with Wilson's disease. Chelators deplete the excessive copper levels in the body by expediting their excretion through urine, but being nonspecific to copper they bind and excrete other micronutrients form the body. The adverse effects related to chelators are severe such as bone marrow suppression and kidney complications thereby hampering its market growth. Zinc acetate is the only mineral recommended as an alternative therapy to chelators. It works by reducing the dietary uptake of copper in the gastrointestinal tract and excretes it through feces. Its effect are extremely slow therefore used for maintenance therapy only.
According to the U.S. Department of Health and Human Services in 2019 countrywide survey the prevalence of Wilson's disease in the United States is 1 in 55,000 births with the Wilson's disease allele frequency rate of 0.00428. North America is the most significant market in the Wilson's disease treatment drugs market on account of high Wilson's disease heterozygote frequency rate of 0.855% in the Caucasian population. The autosomal recessive rate of Wilson's disease is approximately 25% in Europe with patients being resistant to chelators therapy and E.U. approving only zinc acetate for Wilson's disease management in Europe. Being an orphan disease the European Medical Agency is proactively investing in the novel drug discovery for Wilson's disease. The neuropsychiatric indications related to Wilson's disease are on a rise in Asia Pacific. The market is heavily dependent on treatment drugs imported from U.S. and Europe which creates a huge opportunity for the existing generic market in Asia Pacific.
Historical & Forecast Period
This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Wilson's Disease Drugs market are as follows:
Research and development budgets of manufacturers and government spending
Revenues of key companies in the market segment
Number of end users and consumption volume, price and value.
Geographical revenues generate by countries considered in the report:
Micro and macro environment factors that are currently influencing the Wilson's Disease Drugs market and their expected impact during the forecast period.
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.
Market Segmentation
Indication
Hepatic
Neuropsychiatric
Ophthalmic
Others (Heart and Kidney Complications)
Drug Class
Chelators
Penicillamine
Trientine
Minerals
Zinc Acetate
Region Segment (2020-2030; US$ Million)
North America
U.S.
Canada
Rest of North America
UK and European Union
UK
Germany
Spain
Italy
France
Rest of Europe
Asia Pacific
China
Japan
India
Australia
South Korea
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East and Africa
GCC
Africa
Rest of Middle East and Africa
Global Impact of COVID-19 Segment (2020-2021; US$ Million )
Pre COVID-19 situation
Post COVID-19 situation
Key questions answered in this report
What are the key micro and macro environmental factors that are impacting the growth of Wilson's Disease Drugs market?
What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
Estimated forecast and market projections up to 2030.
Which segment accounts for the fastest CAGR during the forecast period?
Which market segment holds a larger market share and why?
Are low and middle-income economies investing in the Wilson's Disease Drugs market?
Which is the largest regional market for Wilson's Disease Drugs market?
What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
Which are the key trends driving Wilson's Disease Drugs market growth?
Who are the key competitors and what are their key strategies to enhance their market presence in the Wilson's Disease Drugs market worldwide?
Table of Contents
1. Preface
- 1.1. Report Description
- 1.1.1. Purpose of the Report
- 1.1.2. Target Audience
- 1.1.3. Key Offerings
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.3.1. Phase I - Secondary Research
- 1.3.2. Phase II - Primary Research
- 1.3.3. Phase III - Expert Panel Review
- 1.3.4. Assumptions
- 1.3.5. Approach Adopted
2. Executive Summary
- 2.1. Market Snapshot: Global Wilson's Disease Drugs Market
- 2.2. Global Wilson's Disease Drugs Market, By Indication, 2021 (US$ Million)
- 2.3. Global Wilson's Disease Drugs Market, By Drug Class, 2021 (US$ Million)
- 2.4. Global Wilson's Disease Drugs Market, By Geography, 2021 (US$ Million)
- 2.5. Attractive Investment Proposition by Geography, 2021
3. Wilson's Disease Drugs Market: Competitive Analysis
- 3.1. Market Positioning of Key Wilson's Disease Drugs Market Vendors
- 3.2. Strategies Adopted by Wilson's Disease Drugs Market Vendors
- 3.3. Key Industry Strategies
- 3.4. Tier Analysis 2021 Versus 2030
4. Wilson's Disease Drugs Market: Macro Analysis & Market Dynamics
- 4.1. Introduction
- 4.2. Global Wilson's Disease Drugs Market Value, 2020 - 2030, (US$ Million)
- 4.3. Market Dynamics
- 4.3.1. Market Drivers
- 4.3.2. Market Restraints
- 4.3.3. Key Challenges
- 4.3.4. Key Opportunities
- 4.4. Impact Analysis of Drivers and Restraints
- 4.5. See-Saw Analysis
5. Wilson's Disease Drugs Market: By Indication, 2020-2030, USD (Million)
- 5.1. Market Overview
- 5.2. Growth & Revenue Analysis: 2021 Versus 2030
- 5.3. Market Segmentation
- 5.3.1. Hepatic
- 5.3.2. Neuropsychiatric
- 5.3.3. Ophthalmic
- 5.3.4. Others (Heart and Kidney Complications)
6. Wilson's Disease Drugs Market: By Drug Class, 2020-2030, USD (Million)
- 6.1. Market Overview
- 6.2. Growth & Revenue Analysis: 2021 Versus 2030
- 6.3. Market Segmentation
- 6.3.1. Chelators
- 6.3.1.1. Penicillamine
- 6.3.1.2. Trientine
- 6.3.2. Minerals
- 6.3.2.1. Zinc Acetate
- 6.3.1. Chelators
7. North America Wilson's Disease Drugs Market, 2020-2030, USD (Million)
- 7.1. Market Overview
- 7.2. Wilson's Disease Drugs Market: By Indication, 2020-2030, USD (Million)
- 7.3. Wilson's Disease Drugs Market: By Drug Class, 2020-2030, USD (Million)
- 7.4.Wilson's Disease Drugs Market: By Region, 2020-2030, USD (Million)
- 7.4.1.North America
- 7.4.1.1. U.S.
- 7.4.1.1.1. Wilson's Disease Drugs Market: By Indication, 2020-2030, USD (Million)
- 7.4.1.1.1. Wilson's Disease Drugs Market: By Drug Class, 2020-2030, USD (Million)
- 7.4.1.2. Canada
- 7.4.1.2.1. Wilson's Disease Drugs Market: By Indication, 2020-2030, USD (Million)
- 7.4.1.2.1. Wilson's Disease Drugs Market: By Drug Class, 2020-2030, USD (Million)
- 7.4.1.3. Rest of North America
- 7.4.1.3.1. Wilson's Disease Drugs Market: By Indication, 2020-2030, USD (Million)
- 7.4.1.3.1. Wilson's Disease Drugs Market: By Drug Class, 2020-2030, USD (Million)
- 7.4.1.1. U.S.
- 7.4.1.North America
8. UK and European Union Wilson's Disease Drugs Market, 2020-2030, USD (Million)
- 8.1. Market Overview
- 8.2. Wilson's Disease Drugs Market: By Indication, 2020-2030, USD (Million)
- 8.3. Wilson's Disease Drugs Market: By Drug Class, 2020-2030, USD (Million)
- 8.4.Wilson's Disease Drugs Market: By Region, 2020-2030, USD (Million)
- 8.4.1.UK and European Union
- 8.4.1.1. UK
- 8.4.1.1.1. Wilson's Disease Drugs Market: By Indication, 2020-2030, USD (Million)
- 8.4.1.1.1. Wilson's Disease Drugs Market: By Drug Class, 2020-2030, USD (Million)
- 8.4.1.2. Germany
- 8.4.1.2.1. Wilson's Disease Drugs Market: By Indication, 2020-2030, USD (Million)
- 8.4.1.2.1. Wilson's Disease Drugs Market: By Drug Class, 2020-2030, USD (Million)
- 8.4.1.3. Spain
- 8.4.1.3.1. Wilson's Disease Drugs Market: By Indication, 2020-2030, USD (Million)
- 8.4.1.3.1. Wilson's Disease Drugs Market: By Drug Class, 2020-2030, USD (Million)
- 8.4.1.4. Italy
- 8.4.1.4.1. Wilson's Disease Drugs Market: By Indication, 2020-2030, USD (Million)
- 8.4.1.4.1. Wilson's Disease Drugs Market: By Drug Class, 2020-2030, USD (Million)
- 8.4.1.5. France
- 8.4.1.5.1. Wilson's Disease Drugs Market: By Indication, 2020-2030, USD (Million)
- 8.4.1.5.1. Wilson's Disease Drugs Market: By Drug Class, 2020-2030, USD (Million)
- 8.4.1.6. Rest of Europe
- 8.4.1.6.1. Wilson's Disease Drugs Market: By Indication, 2020-2030, USD (Million)
- 8.4.1.6.1. Wilson's Disease Drugs Market: By Drug Class, 2020-2030, USD (Million)
- 8.4.1.1. UK
- 8.4.1.UK and European Union
9. Asia Pacific Wilson's Disease Drugs Market, 2020-2030, USD (Million)
- 9.1. Market Overview
- 9.2. Wilson's Disease Drugs Market: By Indication, 2020-2030, USD (Million)
- 9.3. Wilson's Disease Drugs Market: By Drug Class, 2020-2030, USD (Million)
- 9.4.Wilson's Disease Drugs Market: By Region, 2020-2030, USD (Million)
- 9.4.1.Asia Pacific
- 9.4.1.1. China
- 9.4.1.1.1. Wilson's Disease Drugs Market: By Indication, 2020-2030, USD (Million)
- 9.4.1.1.1. Wilson's Disease Drugs Market: By Drug Class, 2020-2030, USD (Million)
- 9.4.1.2. Japan
- 9.4.1.2.1. Wilson's Disease Drugs Market: By Indication, 2020-2030, USD (Million)
- 9.4.1.2.1. Wilson's Disease Drugs Market: By Drug Class, 2020-2030, USD (Million)
- 9.4.1.3. India
- 9.4.1.3.1. Wilson's Disease Drugs Market: By Indication, 2020-2030, USD (Million)
- 9.4.1.3.1. Wilson's Disease Drugs Market: By Drug Class, 2020-2030, USD (Million)
- 9.4.1.4. Australia
- 9.4.1.4.1. Wilson's Disease Drugs Market: By Indication, 2020-2030, USD (Million)
- 9.4.1.4.1. Wilson's Disease Drugs Market: By Drug Class, 2020-2030, USD (Million)
- 9.4.1.5. South Korea
- 9.4.1.5.1. Wilson's Disease Drugs Market: By Indication, 2020-2030, USD (Million)
- 9.4.1.5.1. Wilson's Disease Drugs Market: By Drug Class, 2020-2030, USD (Million)
- 9.4.1.6. Rest of Asia Pacific
- 9.4.1.6.1. Wilson's Disease Drugs Market: By Indication, 2020-2030, USD (Million)
- 9.4.1.6.1. Wilson's Disease Drugs Market: By Drug Class, 2020-2030, USD (Million)
- 9.4.1.1. China
- 9.4.1.Asia Pacific
10. Latin America Wilson's Disease Drugs Market, 2020-2030, USD (Million)
- 10.1. Market Overview
- 10.2. Wilson's Disease Drugs Market: By Indication, 2020-2030, USD (Million)
- 10.3. Wilson's Disease Drugs Market: By Drug Class, 2020-2030, USD (Million)
- 10.4.Wilson's Disease Drugs Market: By Region, 2020-2030, USD (Million)
- 10.4.1.Latin America
- 10.4.1.1. Brazil
- 10.4.1.1.1. Wilson's Disease Drugs Market: By Indication, 2020-2030, USD (Million)
- 10.4.1.1.1. Wilson's Disease Drugs Market: By Drug Class, 2020-2030, USD (Million)
- 10.4.1.2. Mexico
- 10.4.1.2.1. Wilson's Disease Drugs Market: By Indication, 2020-2030, USD (Million)
- 10.4.1.2.1. Wilson's Disease Drugs Market: By Drug Class, 2020-2030, USD (Million)
- 10.4.1.3. Rest of Latin America
- 10.4.1.3.1. Wilson's Disease Drugs Market: By Indication, 2020-2030, USD (Million)
- 10.4.1.3.1. Wilson's Disease Drugs Market: By Drug Class, 2020-2030, USD (Million)
- 10.4.1.1. Brazil
- 10.4.1.Latin America
11. Middle East and Africa Wilson's Disease Drugs Market, 2020-2030, USD (Million)
- 11.1. Market Overview
- 11.2. Wilson's Disease Drugs Market: By Indication, 2020-2030, USD (Million)
- 11.3. Wilson's Disease Drugs Market: By Drug Class, 2020-2030, USD (Million)
- 11.4.Wilson's Disease Drugs Market: By Region, 2020-2030, USD (Million)
- 11.4.1.Middle East and Africa
- 11.4.1.1. GCC
- 11.4.1.1.1. Wilson's Disease Drugs Market: By Indication, 2020-2030, USD (Million)
- 11.4.1.1.1. Wilson's Disease Drugs Market: By Drug Class, 2020-2030, USD (Million)
- 11.4.1.2. Africa
- 11.4.1.2.1. Wilson's Disease Drugs Market: By Indication, 2020-2030, USD (Million)
- 11.4.1.2.1. Wilson's Disease Drugs Market: By Drug Class, 2020-2030, USD (Million)
- 11.4.1.3. Rest of Middle East and Africa
- 11.4.1.3.1. Wilson's Disease Drugs Market: By Indication, 2020-2030, USD (Million)
- 11.4.1.3.1. Wilson's Disease Drugs Market: By Drug Class, 2020-2030, USD (Million)
- 11.4.1.1. GCC
- 11.4.1.Middle East and Africa
12. Company Profile
- 12.1. Kadmon Holdings, Inc.
- 12.1.1. Company Overview
- 12.1.2. Financial Performance
- 12.1.3. Product Portfolio
- 12.1.4. Strategic Initiatives
- 12.2. Merck & Co.
- 12.2.1. Company Overview
- 12.2.2. Financial Performance
- 12.2.3. Product Portfolio
- 12.2.4. Strategic Initiatives
- 12.3. Noble Pharma Co., Ltd.
- 12.3.1. Company Overview
- 12.3.2. Financial Performance
- 12.3.3. Product Portfolio
- 12.3.4. Strategic Initiatives
- 12.4. Teva Pharmaceutical Industries Limited
- 12.4.1. Company Overview
- 12.4.2. Financial Performance
- 12.4.3. Product Portfolio
- 12.4.4. Strategic Initiatives
- 12.5. Tsumura & Co.
- 12.5.1. Company Overview
- 12.5.2. Financial Performance
- 12.5.3. Product Portfolio
- 12.5.4. Strategic Initiatives
- 12.6. Valeant Pharmaceuticals International, Inc.
- 12.6.1. Company Overview
- 12.6.2. Financial Performance
- 12.6.3. Product Portfolio
- 12.6.4. Strategic Initiatives
- 12.7. VHB Life Sciences, Inc.
- 12.7.1. Company Overview
- 12.7.2. Financial Performance
- 12.7.3. Product Portfolio
- 12.7.4. Strategic Initiatives
- 12.8. Wilson's Therapeutics AB
- 12.8.1. Company Overview
- 12.8.2. Financial Performance
- 12.8.3. Product Portfolio
- 12.8.4. Strategic Initiatives
List of Tables
- TABLE 1 Global Wilson's Disease Drugs Market By Indication, 2020-2030, USD (Million)
- TABLE 2 Global Wilson's Disease Drugs Market By Drug Class, 2020-2030, USD (Million)
- TABLE 3 Global Wilson's Disease Drugs Market By Chelators, 2020-2030, USD (Million)
- TABLE 4 Global Wilson's Disease Drugs Market By Minerals, 2020-2030, USD (Million)
- TABLE 5 North America Wilson's Disease Drugs Market By Indication, 2020-2030, USD (Million)
- TABLE 6 North America Wilson's Disease Drugs Market By Drug Class, 2020-2030, USD (Million)
- TABLE 7 North America Wilson's Disease Drugs Market By Chelators, 2020-2030, USD (Million)
- TABLE 8 North America Wilson's Disease Drugs Market By Minerals, 2020-2030, USD (Million)
- TABLE 9 U.S. Wilson's Disease Drugs Market By Indication, 2020-2030, USD (Million)
- TABLE 10 U.S. Wilson's Disease Drugs Market By Drug Class, 2020-2030, USD (Million)
- TABLE 11 U.S. Wilson's Disease Drugs Market By Chelators, 2020-2030, USD (Million)
- TABLE 12 U.S. Wilson's Disease Drugs Market By Minerals, 2020-2030, USD (Million)
- TABLE 13 Canada Wilson's Disease Drugs Market By Indication, 2020-2030, USD (Million)
- TABLE 14 Canada Wilson's Disease Drugs Market By Drug Class, 2020-2030, USD (Million)
- TABLE 15 Canada Wilson's Disease Drugs Market By Chelators, 2020-2030, USD (Million)
- TABLE 16 Canada Wilson's Disease Drugs Market By Minerals, 2020-2030, USD (Million)
- TABLE 17 Rest of North America Wilson's Disease Drugs Market By Indication, 2020-2030, USD (Million)
- TABLE 18 Rest of North America Wilson's Disease Drugs Market By Drug Class, 2020-2030, USD (Million)
- TABLE 19 Rest of North America Wilson's Disease Drugs Market By Chelators, 2020-2030, USD (Million)
- TABLE 20 Rest of North America Wilson's Disease Drugs Market By Minerals, 2020-2030, USD (Million)
- TABLE 21 UK and European Union Wilson's Disease Drugs Market By Indication, 2020-2030, USD (Million)
- TABLE 22 UK and European Union Wilson's Disease Drugs Market By Drug Class, 2020-2030, USD (Million)
- TABLE 23 UK and European Union Wilson's Disease Drugs Market By Chelators, 2020-2030, USD (Million)
- TABLE 24 UK and European Union Wilson's Disease Drugs Market By Minerals, 2020-2030, USD (Million)
- TABLE 25 UK Wilson's Disease Drugs Market By Indication, 2020-2030, USD (Million)
- TABLE 26 UK Wilson's Disease Drugs Market By Drug Class, 2020-2030, USD (Million)
- TABLE 27 UK Wilson's Disease Drugs Market By Chelators, 2020-2030, USD (Million)
- TABLE 28 UK Wilson's Disease Drugs Market By Minerals, 2020-2030, USD (Million)
- TABLE 29 Germany Wilson's Disease Drugs Market By Indication, 2020-2030, USD (Million)
- TABLE 30 Germany Wilson's Disease Drugs Market By Drug Class, 2020-2030, USD (Million)
- TABLE 31 Germany Wilson's Disease Drugs Market By Chelators, 2020-2030, USD (Million)
- TABLE 32 Germany Wilson's Disease Drugs Market By Minerals, 2020-2030, USD (Million)
- TABLE 33 Spain Wilson's Disease Drugs Market By Indication, 2020-2030, USD (Million)
- TABLE 34 Spain Wilson's Disease Drugs Market By Drug Class, 2020-2030, USD (Million)
- TABLE 35 Spain Wilson's Disease Drugs Market By Chelators, 2020-2030, USD (Million)
- TABLE 36 Spain Wilson's Disease Drugs Market By Minerals, 2020-2030, USD (Million)
- TABLE 37 Italy Wilson's Disease Drugs Market By Indication, 2020-2030, USD (Million)
- TABLE 38 Italy Wilson's Disease Drugs Market By Drug Class, 2020-2030, USD (Million)
- TABLE 39 Italy Wilson's Disease Drugs Market By Chelators, 2020-2030, USD (Million)
- TABLE 40 Italy Wilson's Disease Drugs Market By Minerals, 2020-2030, USD (Million)
- TABLE 41 France Wilson's Disease Drugs Market By Indication, 2020-2030, USD (Million)
- TABLE 42 France Wilson's Disease Drugs Market By Drug Class, 2020-2030, USD (Million)
- TABLE 43 France Wilson's Disease Drugs Market By Chelators, 2020-2030, USD (Million)
- TABLE 44 France Wilson's Disease Drugs Market By Minerals, 2020-2030, USD (Million)
- TABLE 45 Rest of Europe Wilson's Disease Drugs Market By Indication, 2020-2030, USD (Million)
- TABLE 46 Rest of Europe Wilson's Disease Drugs Market By Drug Class, 2020-2030, USD (Million)
- TABLE 47 Rest of Europe Wilson's Disease Drugs Market By Chelators, 2020-2030, USD (Million)
- TABLE 48 Rest of Europe Wilson's Disease Drugs Market By Minerals, 2020-2030, USD (Million)
- TABLE 49 Asia Wilson's Disease Drugs Market By Indication, 2020-2030, USD (Million)
- TABLE 50 Asia Wilson's Disease Drugs Market By Drug Class, 2020-2030, USD (Million)
- TABLE 51 Asia Wilson's Disease Drugs Market By Chelators, 2020-2030, USD (Million)
- TABLE 52 Asia Wilson's Disease Drugs Market By Minerals, 2020-2030, USD (Million)
- TABLE 53 China Wilson's Disease Drugs Market By Indication, 2020-2030, USD (Million)
- TABLE 54 China Wilson's Disease Drugs Market By Drug Class, 2020-2030, USD (Million)
- TABLE 55 China Wilson's Disease Drugs Market By Chelators, 2020-2030, USD (Million)
- TABLE 56 China Wilson's Disease Drugs Market By Minerals, 2020-2030, USD (Million)
- TABLE 57 Japan Wilson's Disease Drugs Market By Indication, 2020-2030, USD (Million)
- TABLE 58 Japan Wilson's Disease Drugs Market By Drug Class, 2020-2030, USD (Million)
- TABLE 59 Japan Wilson's Disease Drugs Market By Chelators, 2020-2030, USD (Million)
- TABLE 60 Japan Wilson's Disease Drugs Market By Minerals, 2020-2030, USD (Million)
- TABLE 61 India Wilson's Disease Drugs Market By Indication, 2020-2030, USD (Million)
- TABLE 62 India Wilson's Disease Drugs Market By Drug Class, 2020-2030, USD (Million)
- TABLE 63 India Wilson's Disease Drugs Market By Chelators, 2020-2030, USD (Million)
- TABLE 64 India Wilson's Disease Drugs Market By Minerals, 2020-2030, USD (Million)
- TABLE 65 Australia Wilson's Disease Drugs Market By Indication, 2020-2030, USD (Million)
- TABLE 66 Australia Wilson's Disease Drugs Market By Drug Class, 2020-2030, USD (Million)
- TABLE 67 Australia Wilson's Disease Drugs Market By Chelators, 2020-2030, USD (Million)
- TABLE 68 Australia Wilson's Disease Drugs Market By Minerals, 2020-2030, USD (Million)
- TABLE 69 South Korea Wilson's Disease Drugs Market By Indication, 2020-2030, USD (Million)
- TABLE 70 South Korea Wilson's Disease Drugs Market By Drug Class, 2020-2030, USD (Million)
- TABLE 71 South Korea Wilson's Disease Drugs Market By Chelators, 2020-2030, USD (Million)
- TABLE 72 South Korea Wilson's Disease Drugs Market By Minerals, 2020-2030, USD (Million)
- TABLE 73 Latin America Wilson's Disease Drugs Market By Indication, 2020-2030, USD (Million)
- TABLE 74 Latin America Wilson's Disease Drugs Market By Drug Class, 2020-2030, USD (Million)
- TABLE 75 Latin America Wilson's Disease Drugs Market By Chelators, 2020-2030, USD (Million)
- TABLE 76 Latin America Wilson's Disease Drugs Market By Minerals, 2020-2030, USD (Million)
- TABLE 77 Brazil Wilson's Disease Drugs Market By Indication, 2020-2030, USD (Million)
- TABLE 78 Brazil Wilson's Disease Drugs Market By Drug Class, 2020-2030, USD (Million)
- TABLE 79 Brazil Wilson's Disease Drugs Market By Chelators, 2020-2030, USD (Million)
- TABLE 80 Brazil Wilson's Disease Drugs Market By Minerals, 2020-2030, USD (Million)
- TABLE 81 Mexico Wilson's Disease Drugs Market By Indication, 2020-2030, USD (Million)
- TABLE 82 Mexico Wilson's Disease Drugs Market By Drug Class, 2020-2030, USD (Million)
- TABLE 83 Mexico Wilson's Disease Drugs Market By Chelators, 2020-2030, USD (Million)
- TABLE 84 Mexico Wilson's Disease Drugs Market By Minerals, 2020-2030, USD (Million)
- TABLE 85 Rest of Latin America Wilson's Disease Drugs Market By Indication, 2020-2030, USD (Million)
- TABLE 86 Rest of Latin America Wilson's Disease Drugs Market By Drug Class, 2020-2030, USD (Million)
- TABLE 87 Rest of Latin America Wilson's Disease Drugs Market By Chelators, 2020-2030, USD (Million)
- TABLE 88 Rest of Latin America Wilson's Disease Drugs Market By Minerals, 2020-2030, USD (Million)
- TABLE 89 Middle East and Africa Wilson's Disease Drugs Market By Indication, 2020-2030, USD (Million)
- TABLE 90 Middle East and Africa Wilson's Disease Drugs Market By Drug Class, 2020-2030, USD (Million)
- TABLE 91 Middle East and Africa Wilson's Disease Drugs Market By Chelators, 2020-2030, USD (Million)
- TABLE 92 Middle East and Africa Wilson's Disease Drugs Market By Minerals, 2020-2030, USD (Million)
- TABLE 93 GCC Wilson's Disease Drugs Market By Indication, 2020-2030, USD (Million)
- TABLE 94 GCC Wilson's Disease Drugs Market By Drug Class, 2020-2030, USD (Million)
- TABLE 95 GCC Wilson's Disease Drugs Market By Chelators, 2020-2030, USD (Million)
- TABLE 96 GCC Wilson's Disease Drugs Market By Minerals, 2020-2030, USD (Million)
- TABLE 97 Africa Wilson's Disease Drugs Market By Indication, 2020-2030, USD (Million)
- TABLE 98 Africa Wilson's Disease Drugs Market By Drug Class, 2020-2030, USD (Million)
- TABLE 99 Africa Wilson's Disease Drugs Market By Chelators, 2020-2030, USD (Million)
- TABLE 100 Africa Wilson's Disease Drugs Market By Minerals, 2020-2030, USD (Million)
- TABLE 101 Rest of Middle East and Africa Wilson's Disease Drugs Market By Indication, 2020-2030, USD (Million)
- TABLE 102 Rest of Middle East and Africa Wilson's Disease Drugs Market By Drug Class, 2020-2030, USD (Million)
- TABLE 103 Rest of Middle East and Africa Wilson's Disease Drugs Market By Chelators, 2020-2030, USD (Million)
- TABLE 104 Rest of Middle East and Africa Wilson's Disease Drugs Market By Minerals, 2020-2030, USD (Million)
List of Figures
- FIG. 1 Global Wilson's Disease Drugs Market: Market Coverage
- FIG. 2 Research Methodology and Data Sources
- FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
- FIG. 4 Global Wilson's Disease Drugs Market: Quality Assurance
- FIG. 5 Global Wilson's Disease Drugs Market, By Indication, 2021
- FIG. 6 Global Wilson's Disease Drugs Market, By Drug Class, 2021
- FIG. 7 Global Wilson's Disease Drugs Market, By Geography, 2021
- FIG. 8 Market Geographical Opportunity Matrix - Global Wilson's Disease Drugs Market, 2021
- FIG. 9 Market Positioning of Key Wilson's Disease Drugs Market Players, 2021
- FIG. 10 Global Wilson's Disease Drugs Market - Tier Analysis - Percentage of Revenues by Tier Level, 2021 Versus 2030
- FIG. 11 Global Wilson's Disease Drugs Market, By Indication, 2021 Vs 2030, %
- FIG. 12 Global Wilson's Disease Drugs Market, By Drug Class, 2021 Vs 2030, %
- FIG. 13 U.S. Wilson's Disease Drugs Market (US$ Million), 2020 - 2030
- FIG. 14 Canada Wilson's Disease Drugs Market (US$ Million), 2020 - 2030
- FIG. 15 Rest of North America Wilson's Disease Drugs Market (US$ Million), 2020 - 2030
- FIG. 16 UK Wilson's Disease Drugs Market (US$ Million), 2020 - 2030
- FIG. 17 Germany Wilson's Disease Drugs Market (US$ Million), 2020 - 2030
- FIG. 18 Spain Wilson's Disease Drugs Market (US$ Million), 2020 - 2030
- FIG. 19 Italy Wilson's Disease Drugs Market (US$ Million), 2020 - 2030
- FIG. 20 France Wilson's Disease Drugs Market (US$ Million), 2020 - 2030
- FIG. 21 Rest of Europe Wilson's Disease Drugs Market (US$ Million), 2020 - 2030
- FIG. 22 China Wilson's Disease Drugs Market (US$ Million), 2020 - 2030
- FIG. 23 Japan Wilson's Disease Drugs Market (US$ Million), 2020 - 2030
- FIG. 24 India Wilson's Disease Drugs Market (US$ Million), 2020 - 2030
- FIG. 25 Australia Wilson's Disease Drugs Market (US$ Million), 2020 - 2030
- FIG. 26 South Korea Wilson's Disease Drugs Market (US$ Million), 2020 - 2030
- FIG. 27 Rest of Asia Wilson's Disease Drugs Market (US$ Million), 2020 - 2030
- FIG. 28 Brazil Wilson's Disease Drugs Market (US$ Million), 2020 - 2030
- FIG. 29 Mexico Wilson's Disease Drugs Market (US$ Million), 2020 - 2030
- FIG. 30 Rest of Latin America Wilson's Disease Drugs Market (US$ Million), 2020 - 2030
- FIG. 31 GCC Wilson's Disease Drugs Market (US$ Million), 2020 - 2030
- FIG. 32 Africa Wilson's Disease Drugs Market (US$ Million), 2020 - 2030
- FIG. 33 Rest of Middle East and Africa Wilson's Disease Drugs Market (US$ Million), 2020 - 2030
